Neisseria Meningitidis Infection - 25 Studies Found Completed : One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age : Meningococcal Disease : 2010-06-04 : Biological: rMenB+OMV NZ Subjects will be assigned to a study group based on the group assignment in the Completed : Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers : Meningococcal Disease : 2009-02-18 : Biological: 1a - rMenB+OMV NZ and routine vaccines Completed : Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents : Meningococcal Disease : 2014-05-06 : Biological: MenABCWY Effective Completed : Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules : Meningococcal Disease : 2008-04-16 : Biological: rMenB+OMV NZ Other Completed : Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of Booster Doses of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received One or Four Doses of the Same Vaccine : Meningococcal Disease : 2009-12-04 : Biological: Meningococcal (group B) multicomponent recombinant adsorbed vacc Completed : Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received Three Doses of the Same Vaccine : Meningococcal Disease : 2009-12-04 : Biological: rMenB Biological: rMenB+OMV NZ Completed : A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive. : Prevention of the Meningococcal Disease : 2013-07-26 : Biological: rMenB+OMV NZ Recombinant MenB with Outer Member Vesicle (OMV) from the New Zealand strain Completed : Correlation Between Cytokines and the Severity of Meningococcal Disease : Meningococcemia : 2010-05-27 Recruiting : South Australian Meningococcal B Vaccine Herd Immunity Study : Meningococcal Disease : 2017-03-17 : Biological: Licensed 4CMenB vaccine Two doses (0.5 mL each) of Bexsero ® vaccine at least 1 month t Recruiting : PRIME Follow up - Quadri Meningo Vacinees : Meningococcal Disease : 2016-06-15 : Other: venepuncture only single venepuncture <<< Previous | Next >>>